Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension

Journal of Clinical Hypertension

Volumn 5, Issue 2, 2003, Pages 137-144

  Moore, Michael A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; COUGHING; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; GLOMERULAR DYSFUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART REINFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; QUALITY OF LIFE; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0037366180     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.01040.x     Document Type: Review

References (84)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
2. Hansson L. The hypertension optimal treatment study. Blood Pressure. 1993;2:62-68.
3. Moser M. Is it time for a new approach to the initial treatment of hypertension? Arch Intern Med. 2001;161:1140-1144.
4. Moser M. Diuretics revisited again. Am J Clin Hypertens (Greenwich). 2001;3:136-138.
5. Hypertension Control Rates. Health Plan Employer Data and Information Set (HEDIS) National Quality Assurance Committee. 2003 Annual Report. Available at: www.ncqa.org. Accessed February 6, 2002.
6. Kaplan NM. What is goal blood pressure for the treatment of hypertension? Arch Intern Med. 1992;161:1480-1482.
7. Bloom BS. Continuation of initial antihypertensive medication after one year therapy. Clin Ther. 1998;20(4):1-10.
8. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive classes. Clin Ther. 2002;23:1999-2010.
9. US Renal Data System. USRDS 2002 Annual Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease.
10. Dzau, VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
11. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156:1789-1796.
12. Moore MA, Epstein M, Agadoa L, et al. Current strategies for management of hypertensive renal disease. Arch Intern Med. 1996;159:23-28.
13. Biollaz HR, Brunner I, Gavras B, et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardio Pharmacol. 1982;4(6):966-972.
14. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992;42:1020-1029.
15. Waeber B, Nussberger J, Juillerat L, et al Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity. J Cardiovasc Pharm. 1989;4(14 supp):S53-S59.
16. Baruch L, Anand I, Cohen IS, et al. Augmented short and long term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation. 1999;99:2658-2664.
17. Kaplan NM. Hypertension trials: 1990 to 2000. Curr Opin Nephrol Hypertens. 2000;10(43):501-505.
18. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
19. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13(4 pt 1):418-426.
20. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996;18:608-625.
21. McInnes GT, O'Kane KP, Istad H, et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor lisinopril, in fixed combination with low dose hydrochlorothiazide. J Hum Hypertens. 2000;14:263-269.
22. Neldam S, Forsen B, and Multicenter Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: a 24 week study of the tolerability of candesartan cilexetil in relationship to hydrochlorothiazide. Drugs Aging. 2001;18(3):225-231.
23. Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998;12(8):563-567.
24. Gavras I, Gavras H, and The Eprosartan Study Group. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results 26 week double blind, multicenter study. Curr Med Res Opinion. 1999;15(1):15-24.
25. Veterans Administrative Cooperative Study Group. Veterans Administration Cooperative Study Group on Antihypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
26. Veterans Administration Study Group. Veterans Administration Cooperative Study Group on Antihypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
27. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
28. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
29. Dahloft B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in the hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
30. Hansson L, Lindholm L, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
31. Gottdiener JS, Reda DJ, Massive BM, et al. Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95:1983-1985.
32. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of angiotensin converting enzyme inhibitor enalapril on the long term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD Investigators. Circulation. 1993;88:2277-2283.
33. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
34. Torp-Pedersen C, Kober L, for the TRACE Study Group. Effect of ACE inhibitor trandolpril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet. 1999;354:9-12.
35. Rutherford JD, Pfeffer MA, Moye LA, et al. Coronary heart disease/myocardial infarction: effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. Circulation. 1994;90:1731-1738.
36. Lewis E, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
37. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;34:939-945.
38. Giatras I, Lau J, Levy AS, et al. for the Angiotensin Converting Enzyme Inhibition and Progression Renal Disease Study Group. The effects of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127(5):337-345.
39. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
40. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;36(6):E28-E32.
41. Chobanian AV, Haudenschild CC, Nickerson C, et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
42. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15 (suppl 5):S65-S72.
43. Brown NJ, Vaughn D. Angiotensin-converting enzyme. Circulation. 1998;97:1411-1420.
44. Dahloff B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001;14:174-182.
45. Baruch L, Anand I, Cohen IS, et al. Augmented short and long term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial(V-HeFT) Study Group. Circulation. 1999;99(20):2658-2664.
46. Tonkon M, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy. Irbesartan Heart Failure Group. Intern J Clin Pract. 2000;54(1):11-14.
47. Parker AB, Azevedo ER, Baird MG, et al. Assessment of hemodynamic response in patients with congestive heart failure to telmisartan: a multicenter dose-ranging study. Am Heart J. 1999;138(5):843-848.
48. 1 antagonist eprosartan. Eur J Heart Fail. 2000;2(2):183-187.
49. Yoshimuira M, Yasue H. Hemodynamic and hormonal effects of angiotensin II antagonist, candesartan cilexetil in patients with congestive heart failure. Cardiology. 2000;93(3):175-182.
50. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
51. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic and tolerability: Losartan Hemodynamic Study Group. Circulation. 1995:91:691-697.
52. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors. Am Heart J. 2000;139:609-617.
53. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997;349:747-752.
54. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the losartan heart failure survival trial Elite II. Lancet. 2000;355:1582-1587.
55. Cohn J, Tognoni G, and Val-HeFT Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2002;345:1667-1675.
56. Cottone C, Parrinello G, Follone G, et al. Effects of losartan on cardiac performance during treadmill exercise in hypertensive subjects [abstract]. Am J Hypertens. 1997;10:137A.
57. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 1997;30:983-991.
58. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
59. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonists irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
60. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056-1064.
61. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet. 2002;360(9335):752-760.
62. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med. 2001;161:1492-1499.
63. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20(1):71-78.
64. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
65. Heras N, Aragoncillo P, Maeso R, et al. AT-1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension. 1999;34(2):969-975.
66. Peters S, Gotting B, Trummel M, et al. Valsartan for prevention of restenosis after stenting type B2/C lesions: the Val-PREST trial. J Invas Cardiol. 2001;13:93-97.
67. Lebrillant E, Roulet MJ, Robert R, et al. Study of anti-atherogenic properties of indapamide, a pharmacologic model. J Cardio Pharm. 1993;22 (suppl 6):S53-S56.
68. Makris TK, Stacroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan and atenolol. Am J Hypertens. 2000;13(7):783-788.
69. Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol. 2000;86:1188-1192.
70. Plat F, Sainin R. Management of hypertension: the role of combination therapy. Am J Hypertens. 1997;10:262S-271S.
71. Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low-and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:17-24.
72. Reams GP, Bauer JH. Long-term effects of enalapril monotherapy and enalapril/hydrochlorothiazide combination therapy on blood pressure, renal function, and body fluid composition. J Clin Hypertens (Greenwich). 1986;2: 55-63.
73. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278-285.
74. Kochar M, Zablocki CJ, Guthrie R, et al. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1997;10:106A.
75. Physician's Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc; 2001:654-566, 996-998, 1902-1904, 2166-2168.
76. Grimm RH Jr, Grandis GA, Cutler JA, et al. Relationships of quality of life measures to long term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157:638-648.
77. Paran E, Anson O, Neuman L. The effects of replacing beta-blockers with an angiotensin-converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens. 1996;9:1206-1213.
78. Sebastian JL, McKinney WP, Kaufman J, et al. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient clinic population. Chest. 1991;99:36-39.
79. Moore MA, Edelman JM, Gazdick LP, et al. Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: a community-based study of losartan-based regimen vs. usual care. High Blood Press. 1998;7: 156-167.
80. Vidal JLL, Vicente JVL, Roca JA, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321:336-341.
81. Phelps KR, Lieberman RL, Oh MS, et al. Pathophysiology of the syndrome of hyporeninemic hypoaldosteronism. Metabolism. 1980;29:186-199.
82. Franse LV, Pahor M, DiBari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35(5):1025-1030.
83. Soffer BA, Wright JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
84. Black HR, Graff A, Glazer R, et al. Reduced diuretic induced hypokalemia with valsartan in combination with HCTZ [abstract]. Am J Hypertens. 1999;12(4):127A.